Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | S100A9 | P06702 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21847399 | 0.79 | APP (0.39) | DHODHS1PR1S1PR3MEN1HTT | |
| SCHEMBL31317020 | 0.78 | HTT (0.46) | MEN1HTTKMT2AHSD17B10CYP2C9 | |
| SCHEMBL1198968 | 0.78 | HTT (0.46) | MEN1HTTKMT2AHSD17B10CYP2C9 | |
| SCHEMBL968702 | 0.78 | ALDH1A1 (0.35) | MEN1KMT2APIK3CASYK | |
| SCHEMBL29572771 | 0.78 | ALDH1A1 (0.35) | MEN1KMT2APIK3CASYK | |
| SCHEMBL2698119 | 0.78 | BACE1 (0.41) | DHODHHTTHSD17B10IDO1 | |
| Hydrochloric Acid SCHEMBL28482242 | 0.78 | APP (0.38) | DHODHS1PR1S1PR3MEN1HTT | |
| Water SCHEMBL28877782 | 0.77 | HTT (0.45) | MEN1HTTKMT2AHSD17B10PLAU | |
| Water SCHEMBL29974467 | 0.77 | HTT (0.45) | MEN1HTTKMT2AHSD17B10PLAU | |
| SCHEMBL1164963 | 0.75 | HTT (0.37) | MEN1HTTKMT2AHSD17B10IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114540846-B | Synthesis method of 1,2, 4-triazolo six-membered nitrogen heterocycle-3-amine | 五邑大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-114540846-A | Synthetic method of 1,2, 4-triazolo hexa-nitrogen heterocyclic-3-amine | 五邑大学 | 2022-05-27 | — | — | CN | disclosed |
| US-11339160-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339160-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3914348-A1 | IMIDAZO[1,5-A]PYRIDINE, 1,2,4-TRIAZOLO[4,3-A]PYRIDINE AND IMIDAZO[1,5-A]PYRAZINE AS JAK INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-113498352-A | Imidazo [1,5-A ] pyridines, 1,2, 4-triazolo [4,3-A ] pyridines and imidazo [1,5-A ] pyrazines as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20210040085-A1 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-11 | — | — | US | disclosed |
| US-20210040085-A1 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-11 | — | — | US | disclosed |
| US-10851102-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851102-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7220863-B2 | Process for preparing 2-aminopyridine derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-05-22 | — | — | US | disclosed |
| US-20060047124-A1 | Process for preparing 2-aminopyridine derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-03-02 | — | — | US | disclosed |
| US-20020156285-A1 | Novel herbicides | KUNZ WALTER (CH) | 2002-10-24 | — | — | US | disclosed |
| US-6369002-B1 | HETERO IS PYRIMIDINE OR PYRIDAZINE; 1-(3-FLUORO-5-CHLORO PYRIDIN-2-YL)-3-METHYL-4-TRIFLUOROMETHYLPYRIMIDIN-2,6-DIONE | SYNGENTA CROP PROPERTIES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002015902-A1 | METHOD OF TREATING OR PREVENTING URINARY INCONTINENCE USING PROSTANOID EP1 RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-1076656-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | Novartis AG (CH) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055693-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | DHODH 304/4885S1PR1 2252/4885S1PR3 2222/4885 |
| US-20060047124-A1 | Process for preparing 2-aminopyridine derivatives | KCND2, KCNJ2, KCNJ5 | DHODH 613/4885S1PR1 3737/4885S1PR3 3341/4885 |
| US-20020156285-A1 | Novel herbicides | DDT, CBR1, CBR3 | DHODH 768/4885S1PR1 3541/4885S1PR3 3620/4885 |
| US-10851102-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | JAK3, JAK1, JAK2 | DHODH 2847/4885S1PR1 2248/4885S1PR3 883/4885 |
| US-11339160-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | JAK3, JAK1, JAK2 | DHODH 2847/4885S1PR1 2248/4885S1PR3 883/4885 |
| US-20210040085-A1 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | DHODH 2847/4885S1PR1 2248/4885S1PR3 883/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | DHODH 304/4885S1PR1 2252/4885S1PR3 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.